Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane
(Houston -- June 11, 2004) US Oncology (Nasdaq: USON) announced that data presented this week by a network physician at the American Society of Clinical Oncology annual meeting demonstrate that the investigational drug Abraxane (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease h...European Commission approves Herceptin + Taxotere as 1st-line therapy in HER2-positive breast cancer
Roche announced today that the European Commission has approved the use of Herceptin (trastuzumab) in combination with Taxotere (docetaxel) in the European Union as a first-line therapy in HER2-positive metastatic breast cancer patients who have not yet received chemotherapy for their disease. HER2-positive breast cancer patients suffer from a particularly aggressive form of breast cancer which t...APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
NEW ORLEANS, LA; SCHAUMBURG, IL June 7, 2004 Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. (APP) (NASDAQ: APPX) today said that results from a 106 patient Phase II study of ABRAXANE in patients with advanced breast cancer whose disease had progressed while they were being treated with TAXOL and Taxotere responded to subsequent treatment with ABRAXANE (albumin nanoparti...